Advanced

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

Andreasen, N; Minthon, Lennart LU ; Vanmechelen, E; Vanderstichele, H; Davidsson, P; Winblad, B and Blennow, K (1999) In Neuroscience Letters 273(1). p.5-8
Abstract
We studied CSF-tau and CSF-Abeta42 in 16 patients with mild cognitive impairment (MCI) who at follow-up investigations 6-27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-Abeta42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Neuroscience Letters
volume
273
issue
1
pages
5 - 8
publisher
Elsevier
external identifiers
  • scopus:0032857103
ISSN
0304-3940
DOI
10.1016/S0304-3940(99)00617-5
language
English
LU publication?
yes
id
6cfde800-2612-4897-98c8-5486614d215a (old id 1296634)
date added to LUP
2009-07-31 14:51:16
date last changed
2017-07-30 03:37:03
@article{6cfde800-2612-4897-98c8-5486614d215a,
  abstract     = {We studied CSF-tau and CSF-Abeta42 in 16 patients with mild cognitive impairment (MCI) who at follow-up investigations 6-27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-Abeta42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase.},
  author       = {Andreasen, N and Minthon, Lennart and Vanmechelen, E and Vanderstichele, H and Davidsson, P and Winblad, B and Blennow, K},
  issn         = {0304-3940},
  language     = {eng},
  number       = {1},
  pages        = {5--8},
  publisher    = {Elsevier},
  series       = {Neuroscience Letters},
  title        = {Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment},
  url          = {http://dx.doi.org/10.1016/S0304-3940(99)00617-5},
  volume       = {273},
  year         = {1999},
}